Clinical Tumor Anemia Registry (TAR)
Solo los usuarios registrados pueden traducir artículos
Iniciar sesión Registrarse
El enlace se guarda en el portapapeles.
EstadoTerminado
Patrocinadores
iOMEDICO AG
Colaboradores
ASORS (Arbeitsgemeinschaft Supportive Maßnahmen in der Onkologie, Rehabilitation und Sozialmedizin der Deutschen Krebsgesellschaft)
ENSAYO CLÍNICO: NCT01795690
BioSeek: NCT01795690
Palabras clave
Abstracto
The purpose of this registry is to record information of routine treatment of anemia in cancer patients in Germany. An overview of the current treatment of anemia in German outpatient centers and hospitals will be provided. Primary outcome parameters, e.g. improvement in hemoglobin levels and changes in QoL, as well as patient characteristics of different treatments will be analyzed.
fechas
| Verificado por última vez: | 11/30/2014 |
| Primero enviado: | 10/07/2012 |
| Inscripción estimada enviada: | 02/17/2013 |
| Publicado por primera vez: | 02/20/2013 |
| Última actualización enviada: | 02/25/2016 |
| Última actualización publicada: | 02/28/2016 |
| Fecha de inicio real del estudio: | 11/30/2011 |
| Fecha estimada de finalización primaria: | 08/31/2013 |
| Fecha estimada de finalización del estudio: | 01/31/2016 |
Condición o enfermedad
Anemia
Fase
-
Criterio de elegibilidad
| Edades elegibles para estudiar | 18 Years A 18 Years |
| Sexos elegibles para estudiar | All |
| Método de muestreo | Non-Probability Sample |
| Acepta voluntarios saludables | si |
| Criterios | Inclusion Criteria: - Histologically confirmed malignant disease - Hemoglobin level < 11 g/dl (female) or < 12 g/dl (male) - Start of antianemic therapy no more than 7 days prior to informed consent - Performance status 0 - 3 (Karnofsky-Index >= 40%) - Minimum age: 18 years - Informed written consent Exclusion Criteria: - Hypersensitivity against antianemic therapies - Myelodysplastic Syndrome - Experimental antianemic therapy |
Salir
Medidas de resultado primarias
1. Documentation of therapies [12 weeks per patient]
Overview on the current routine treatment of anemia in cancer patients in Germany
Medidas de resultado secundarias
1. Change in hemoglobin levels and QoL [12 weeks per patient]
Effectiveness of different antianemic treatments is investigated by measuring increase of hemoglobin levels and QoL (FACT-An and FACT-GP).
Baseline in hemoglobin (before treatment) is compared with hemoglobin levels after treatment. Each patient is followed for a maximum of 12 weeks to obtain data about the course of the treatment.
